在慢性髓性白血病中潜在的治疗点
1School of Biotechnology, Banaras Hindu University, Varanasi, U.P., 221005, India.
Medical oncology (Northwood, London, England)
|July 17, 2025
概括
需要新的策略来克服慢性髓性白血病 (CML) 中对氨酸激酶抑制剂 (TKIs) 的耐药性. 准氧化应激,亡和使用基因编辑等途径为治愈性CML治疗提供了有希望的途径.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 是由BCR::ABLcoprotein驱动的,与氨酸激酶抑制剂 (TKIs) 改善了生存率.
- 对TKIs的耐药性,白血病干细胞的持久性和复发需要替代治疗策略.
- 氧化应激途径与CML的发展和耐药性有关,是干预的目标.
研究的目的:
- 审查CML治疗的技术知识之外的有希望的治疗目标.
- 探索新的方法,包括抑制路径,自,BCL-2家族蛋白质和microRNAs.
- 讨论基因编辑和USP抑制,以克服耐药性并实现治愈结果.
主要方法:
- 对CML的当前和新兴治疗策略的文献综述.
- 分析涉及CML病原和治疗耐药性的分子途径.
- 探索新的标,如瘤抑制剂,自,BCL-2蛋白和microRNAs.
主要成果:
- 恢复瘤抑制功能 (PTPRG,p53) 可以增强亡并补充TKI.
- 调节自和向BCL-2家族蛋白质提供了克服亡抵抗的方法.
- 微RNAs (miRNAs) 通过调节瘤和亡途径,为先进的治疗提供了机会.
结论:
- 结合新的治疗方法与下一代技术知识的结合对于CML更深层次的缓解至关重要.
- 基因编辑和USP抑制是针对瘤驱动因素和克服耐药性的新兴策略.
- 个性化和全面的治疗策略对于在CML患者中实现治愈结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:15Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:26Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K